Zinc carnosine (polaprezinc) is a chelated compound of zinc and L-carnosine with specific clinical evidence for cytoprotective action on the gastric and intestinal mucosa. Antibiotics increase intestinal permeability and damage the mucosal layer independently of the bacterial disruption they cause. Zinc carnosine repairs this structural damage through direct mucosal adhesion and anti-inflammatory action. No probiotic strain addresses this mechanism, which is why it is a distinct component of the Aegis Protocol formulation rather than an additional probiotic strain.
What zinc carnosine actually is
Zinc carnosine is not simply zinc and carnosine mixed together. The two are chelated, meaning zinc ions are chemically bonded to carnosine molecules to form a stable polymer complex. This chelation changes the compound's behaviour significantly from either component alone.
Carnosine on its own is a dipeptide of beta-alanine and histidine, found in muscle tissue and the gut. Zinc on its own is an essential mineral with broad physiological roles. When chelated, the resulting compound has mucoadhesive properties that neither component possesses individually. It binds specifically to the mucosal lining of the gastrointestinal tract and releases its components locally over an extended period, targeting the gut wall directly rather than being absorbed into systemic circulation.
The compound is also marketed under the trade name Polaprezinc and has been used in clinical gastroenterology in Japan since the 1990s, initially for peptic ulcer treatment. The mechanism of action that makes it useful for ulcer healing is the same mechanism that makes it relevant to post-antibiotic gut lining repair.
What antibiotics do to the gut lining
Most discussion of antibiotic side effects focuses on the microbiome. The structural damage to the gut lining itself is less discussed but equally important for full recovery.
The intestinal epithelium is a single-cell-thick layer forming the barrier between your gut contents and your bloodstream. These cells are held together by tight junction proteins including claudin, occludin, and zonula occludens. Antibiotics disrupt this architecture through two mechanisms. Direct chemical irritation from the drug itself and its metabolites can damage epithelial cells. And the loss of beneficial gut bacteria, which produce short-chain fatty acids (SCFAs) that serve as the primary fuel for epithelial cells, starves the gut lining of its energy source.
The result is increased intestinal permeability, sometimes called leaky gut, where substances that should remain in the gut lumen pass through gaps in the epithelial barrier. This triggers a local immune response and contributes to the cramping and discomfort of post-antibiotic gut symptoms. It also means the gut lining needs repair as well as reseeding with beneficial bacteria.
The clinical evidence
A 2011 study published in the journal Biochemistry and Biophysics Research Communications examined zinc carnosine's effects on intestinal permeability in vitro and in animal models. The compound significantly reduced permeability and protected tight junction integrity against chemical damage. The authors identified the mechanism as both anti-inflammatory and direct stabilisation of the tight junction protein network.
A 2013 randomised controlled trial published in Gut examined zinc carnosine in patients with non-steroidal anti-inflammatory drug (NSAID)-induced intestinal permeability. NSAID-induced gut damage has a similar mechanism to antibiotic-induced damage: both involve direct chemical injury to the epithelium and disruption of the mucosal layer. The zinc carnosine group showed significant reduction in intestinal permeability markers compared to placebo.
Research by Mahmood and colleagues at the University of Birmingham demonstrated zinc carnosine's specific cytoprotective action on human intestinal epithelial cells, showing it stimulates heat shock proteins in the gut lining, which are the cellular repair proteins that protect against stress and accelerate recovery from injury.
The mechanism of protecting and repairing the intestinal barrier is well-established in the clinical literature. The application to post-antibiotic gut recovery is a logical extension of this evidence, addressing a mechanism that is clearly active in antibiotic-induced gut damage but that no probiotic strain specifically targets.
Why not just take a zinc supplement?
This is a reasonable question and the answer is in the chelation chemistry.
Regular zinc supplements, whether zinc gluconate, zinc sulfate, or zinc oxide, are absorbed primarily in the small intestine into systemic circulation. They raise serum zinc levels and address systemic zinc deficiency. They do not specifically target the gut mucosal layer because they are absorbed before reaching the colon and because they lack the mucoadhesive properties of the chelated compound.
Zinc carnosine's polymer structure gives it a much longer residence time in the gut lumen and mucosa. It stays at the site where the damage is. The local zinc and carnosine concentrations at the mucosal level are substantially higher with polaprezinc than with equivalent doses of zinc gluconate. This localised action is what produces the mucosal repair effects.
The dose in the Aegis Protocol
The clinically studied dose of zinc carnosine for gut mucosal repair is 75mg per day. The Aegis Protocol AM Shield capsule contains 75mg of zinc carnosine (polaprezinc), consistent with the dose used in the published clinical trials. At this dose, the elemental zinc content is approximately 16mg, which is within the FSSAI upper safe limit for zinc supplementation and well below the tolerable upper intake level set by ICMR.
The AM timing is deliberate. Taking zinc carnosine in the morning with breakfast means it reaches the gut when it has been fasted overnight, at the moment when the mucosal lining has had maximum recovery time and when the protective effect through the day is most relevant to meal-induced gut stress during the recovery period.
Safety
Zinc carnosine has an excellent safety record in the clinical literature. It has been used therapeutically in Japan for over 30 years with no significant adverse events recorded in the published literature. Mild nausea is occasionally reported at higher doses. At the 75mg dose used in the Aegis Protocol, adverse events in clinical trials were comparable to placebo.
The compound should not be taken at very high doses for extended periods as excessive zinc supplementation can interfere with copper absorption. At the 75mg dose for a 14-day protocol, this is not a practical concern.
Free resource
The 14-Day Post-Antibiotic Recovery Guide
Covers the full formulation rationale, AM/PM protocol timing, and what to expect during each phase of recovery.
Read the guide →The summary
Zinc carnosine is in the Aegis Protocol formulation because post-antibiotic gut recovery requires more than restoring bacterial populations. The structural damage to the gut lining is a distinct mechanism that probiotics cannot address. Zinc carnosine's mucoadhesive properties, its specific cytoprotective action on intestinal epithelial cells, and its clinical evidence for gut barrier repair make it the correct tool for this specific aspect of recovery. It addresses the part of the problem that S. boulardii and LGG, for all their clinical strength, are not designed to fix.